Intravenous L-citrulline- Asklepion

Drug Profile

Intravenous L-citrulline- Asklepion

Alternative Names: L-citrulline

Latest Information Update: 05 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vanderbilt University
  • Developer Asklepion Pharmaceuticals
  • Class Amino acids; Diamino amino acids
  • Mechanism of Action Amino acid replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Acute lung injury

Most Recent Events

  • 01 Aug 2016 Asklepion initiates enrolment in a phase III trial for Acute lung injury (In Infants, In children, In adolescents, Prevention) in USA (NCT02891837)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top